Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Oral Hypoglycemic Agents: Sulfonylureas

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Novel concept suppressing plasma heat pulses in a tokamak by fast divertor sweeping.

Scientific reports·2022

Same author

Preparation for fatherhood: A role for olfactory communication during human pregnancy?

Physiology & behavior·2019

Same author

Patterns of MHC-dependent mate selection in humans and nonhuman primates: a meta-analysis.

Molecular ecology·2016

Same author

Edge Thomson scattering diagnostic on COMPASS tokamak: installation, calibration, operation, improvements.

The Review of scientific instruments·2014

Same author

Introducing minimum Fisher regularisation tomography to AXUV and soft x-ray diagnostic systems of the COMPASS tokamak.

The Review of scientific instruments·2012

Same author

Manipulation of body odour alters men's self-confidence and judgements of their visual attractiveness by women.

International journal of cosmetic science·2009

Search research articles

Related Experiment Video

Updated: Jul 11, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Pioglitazone impurities.

J Richter¹, J Jirman, J Havlícek

¹Department of Technology of Organic Compunds, Faculty of Chemical Technology, Univerzity of Pardubice, Czech Republic. Jindrich.richter@zentiva.cz

|September 18, 2007

Summary

This summary is machine-generated.

This study details the preparation of pioglitazone active pharmaceutical ingredient (API), focusing on impurity formation. Four key impurities were synthesized and characterized using Nuclear Magnetic Resonance (NMR) spectroscopy.

Related Experiment Videos

Last Updated: Jul 11, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Area of Science:

Pharmaceutical Chemistry
Organic Synthesis
Analytical Chemistry

Background:

Pioglitazone is an important antidiabetic drug.
Controlling impurities in Active Pharmaceutical Ingredients (APIs) is critical for drug safety and efficacy.
Understanding impurity profiles aids in optimizing synthesis routes.

Purpose of the Study:

To investigate methods for preparing pioglitazone API with a focus on impurity occurrence.
To synthesize and characterize four specific impurities of pioglitazone.

Main Methods:

Discussion of pioglitazone preparation methods.
Synthesis of four real pioglitazone impurities.
Characterization using Nuclear Magnetic Resonance (NMR) spectroscopy.

Main Results:

Identification and structural elucidation of four pioglitazone impurities (I-IV).
NMR spectroscopy confirmed the structures of the synthesized impurities.
Insights into impurity formation during pioglitazone synthesis.

Conclusions:

The study successfully prepared and characterized key impurities of pioglitazone.
This work provides valuable data for controlling impurity levels in pioglitazone manufacturing.
Characterization of impurities is essential for quality control in pharmaceutical production.